Suchergebnisse - "Tabak, Fehmi"

PubPharm (16)

11

Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b : relation to response and HBV genotype

enthalten in: Antiviral therapy | 2012

von Sonneveld, M. | Rijckborst, V. | Cakaloglu, Y. | +8

12

Pegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis

enthalten in: The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology | 2012

von Kabaçam, G. | Dalekos, G. | Çakaloğlu, Y. | +12

13

A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B

enthalten in: The American journal of gastroenterology | 2010

von Rijckborst, V. | ter Borg, M. | Cakaloglu, Y. | +58

CommentIn: Am J Gastroenterol. 2010 Aug;105(8):1770-2. - PMID 20686463

14

Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels

enthalten in: Hepatology (Baltimore, Md.) | 2010

von Rijckborst, V. | Hansen, B. | Cakaloglu, Y. | +11

15

Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b

enthalten in: Gastroenterology | 2008

von Buster, E. | Flink, H. | Cakaloglu, Y. | +12

16

Correlation of quantitative assay of HBsAg and HBV DNA levels during chronic HBV treatment

enthalten in: Digestive diseases and sciences | 2008

von Ozaras, R. | Tabak, F. | Tahan, V. | +4